

Contact Info:

John Kasha, Acting CEO (USA)

Phone: 703-867-1886, Email: [john.kasha@kashalaw.com](mailto:john.kasha@kashalaw.com)

Web: <http://www.kashalaw.com/physiosign>



EXECUTIVE SUMMARY

OVERVIEW

Market Size: \$4-15 Billion
Revenue 2019: \$3.5 Million
Business Model: Medical Device Sales and Services

INVESTMENT CASE

- Addresses No. 1 Cause of Death - Heart Disease
Addresses No. 1 Healthcare Problem - Cost
Applies No. 1 Healthcare Technology - AI

BOARD MEMBERS

Dr. Gary Chen, Founder and Chairman
Dr. Rong Yang
Atty. John Kasha

R&D Team and Scientists

Dr. Gary Chen
Dr. Rong Yang
Eric Jiang
David Xing
Michael Hong
Jeff Kuang
JC Chen
DK Song

FINANCING SOUGHT

\$25-30 Million

CURRENT INVESTORS

Dr. Gary Chen

USE OF FUNDS



- Grow Sales in China
Increase Sales Force
Increase Customer Service
Grow Inventory
Expand Outside of China
Obtain Regulatory Approvals
Add U.S. and European Offices

IP

- 8 U.S. Patents
More Patent Applications pending
Trade Secrets
Database of more than 1.5 million patient and animal studies

Clinically Proven

- In the clinic in China and in peer-reviewed journal articles




SAAH waveform detected by PhysioSign's AI-EKG/ECG device. This SAAH waveform includes subwaveforms corresponding to internal structures of the heart. For example, subwaveforms a, b, c, d, and e correspond to the internal structures of the heart shown on the left. This detection of subwaveforms was predicted in the 1960s. PhysioSign has not only figured out how to record them, it has figured out how to use them to predict heart disease. Using unique AI software, PhysioSign's AI-EKG/ECG device compares the added data for the subwaveforms of a patient to its database of normal and abnormal subwaveforms gathered from more than 1.5 million patient and animal studies. From this comparison, PhysioSign's device can now diagnose diseases like CAD with greater accuracy.

Business Description: PhysioSign Inc. is a medical device company focused on the development of a new AI-EKG/ECG device that can automatically diagnose coronary artery disease (CAD) and other heart diseases with accuracies of greater than 90%.

Problem: Data drives AI. On the left is the well-known PQRST ECG waveform for which Einthoven won a Nobel Prize in 1924. Unfortunately, this waveform reveals little information about the internal structures of the heart, which is critical to disease diagnosis and critical to providing more data for AI.

Solution: On the right is the SAAH ECG waveform detected by PhysioSign's AI-EKG/ECG device. This SAAH waveform includes subwaveforms corresponding to internal structures of the heart. For example, subwaveforms a, b, c, d, and e correspond to the internal structures of the heart shown on the left. This detection of subwaveforms was predicted in the 1960s. PhysioSign has not only figured out how to record them, it has figured out how to use them to predict heart disease. Using unique AI software, PhysioSign's AI-EKG/ECG device compares the added data for the subwaveforms of a patient to its database of normal and abnormal subwaveforms gathered from more than 1.5 million patient and animal studies. From this comparison, PhysioSign's device can now diagnose diseases like CAD with greater accuracy.




For Patients: Heart diseases like CAD are detected sooner, testing is more comfortable since ECG is noninvasive, and lives will be saved.

For Clinicians: PhysioSign's device takes the guesswork out of reading the PQRST waveform, saves time, and improves patient outcomes.

For Healthcare Costs: A reduction of cost by, at least, a factor of 50 is possible by moving disease diagnosis from an invasive procedure to a noninvasive procedure.

Business Market / Model: The global ECG Device Market in 2017 was \$3.95 Billion and is expected to grow to \$6.79 Billion by 2026. The global Heart Attack Diagnostic Market is expected to exceed \$15.4 Billion by 2024. These numbers are based on existing ECG devices that essentially have not changed in more than 100 years. PhysioSign's device includes breakthrough technology that allows it to span both markets. Like its device, PhysioSign's business model is also unique. The device has been developed in stealth mode and is only offered for sale in China. It has already generated revenue there with negotiations underway for more than \$80 million in sales. As a result, PhysioSign presents a unique opportunity for investors by allowing them to invest in a new medical device and almost immediately participate in sales of that device. Of course, PhysioSign's device will be subject to regulatory approval in many other countries. However, regulatory approval of medical devices is based on compatibility with existing devices. Since PhysioSign's device also produces the standard PQRST waveform, regulatory approval is expected to be straightforward and timely.



Vision: PhysioSign's goal is to become the global leader in EKG/ECG technology. On the left is the new EpCG waveform.

Competition: Others have applied AI to EKG/ECG, but no one else has the added AI data provided by the detected subwaveforms.